

INVESTOR RELATIONS

MetrioPharm Investor Relations News QII 2021

15th Annual General Meeting of MetrioPharm AG

On May 20, 2021, the 15th Annual General Meeting of MetrioPharm AG took place, in accordance with the Covid 19 Regulation 3 issued by the Federal Council, without physical participation of the shareholders, but with the involvement of the lawful representation of all necessary entities.

After approval of the annual report and the financial statements 2020 and the discharge of the Board of Directors, Messrs. Rudolf Stäger, Ekkehard Brysch and Jörg Gruber were reelected to the Board of Directors for three consecutive years.

Of the total share capital of CHF 32,207,709.00, divided into 161,038,545 registered shares with a par value of CHF 0.20 each, 118,228,526 shares were represented. This corresponds to 73.42% of the shares issued. The voting results for the 15th Annual General Meeting are listed [in detail on our website](#).

We would like to take this opportunity to thank all shareholders for their cooperation, without whose commitment the proceedings would not have gone so smoothly. We hope that we will be able to welcome you all in person to the Annual General Meeting of 2022.

MetrioPharm in the Media

During the past quarter, we were able to successfully place MetrioPharm in the media on three occasions again. The main topic of all publications was the global Covid-19 pandemic.

On April 6, 2021, a commentary titled "From Pandemic to Therapy" by MetrioPharm's CEO Dr. Wolfgang Brysch was published in the Berlin-based daily, "[Tagesspiegel](#)". Dr. Brysch argues that as a long-term Corona strategy, the general focus must be on developing therapeutics to treat Covid-19.

On May 26, 2021, another opinion piece "Testing new therapies faster and still safely" was published in the "[Frankfurter Rundschau](#)". In this article, Dr. Brysch discusses the procedural standardization of clinical trials to enable a faster development of therapeutics.

INVESTOR RELATIONS

On June 26, 2021, MetrioPharm was mentioned in the piece "Underestimated Corona Therapeutics" in the Swiss business newspaper "[Finanz und Wirtschaft](#)". Here, author Rupen Boyadjian describes individual companies setting up clinical trials for corona therapeutics and the urgent need for those treating patients, worldwide.

Your contact:



Lia Petridou
Corporate Communications & Press Relations
T +49 (0) 30 33 84 395 53
F +49 (0) 30 33 84 395 99
E press@metriopharm.com
W www.metriopharm.com